
Quarterly revenue rose 12%, while exceptional charges tied to US litigation and the proposed Organon acquisition weighed on reported earnings.
Sun Pharmaceutical Industries reported a 36% year-on-year decline in consolidated net profit to Rs 1,989 crore for the September quarter. Revenue from operations rose 12% to Rs 16,199 crore.
The company recognized Rs 1,269 crore in exceptional charges, largely related to a US generic-drug pricing litigation settlement and costs for its proposed Organon acquisition. Excluding exceptional items, net profit increased 1% to Rs 3,162 crore.
EBITDA rose 5% to Rs 4,744 crore, while the EBITDA margin narrowed to 29.3% from 31.3% a year earlier. Domestic formulations sales increased 17% to Rs 5,552 crore, and the company launched 14 products in India during the quarter.
US formulations sales fell 8.2% to $455 million, mainly because of lower lenalidomide sales, the company said. Excluding that drug, US sales increased marginally. Global innovative medicines sales rose 6.9% to $356 million.
As of 9:58 UTC on Friday, Sun Pharma shares traded at Rs 1,777.70, up 0.95% since the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.